Pharmavac MXT lyofilizát a rozpúšťadlo na injekčnú suspenziu
Pharmavac MXT lyofilizát a rozpúšťadlo na injekčnú suspenziu
Authorised
- Myxoma virus, Live
Product identification
Medicine name:
Pharmavac MXT lyofilizát a rozpúšťadlo na injekčnú suspenziu
Active substance:
- Myxoma virus, Live
Target species:
-
Rabbit
Route of administration:
-
Subcutaneous use
-
Intradermal use
Product details
Active substance and strength:
-
Myxoma virus, Live4.20/log10 tissue culture infective dose 500.50millilitre(s)
Pharmaceutical form:
-
Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
-
Subcutaneous use
-
Rabbit
-
All relevant tissues0dayzero days
-
-
-
Intradermal use
-
Rabbit
-
All relevant tissues0dayzero days
-
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI08AD02
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Slovakia
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
- Pharmagal Bio spol. s r.o.
Marketing authorisation date:
Manufacturing sites for batch release:
- Pharmagal Bio spol. s r.o.
Responsible authority:
- Institute For State Control Of Veterinary Biologicals And Medicaments
Authorisation number:
- 97/121/99-S
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Combined File of all Documents
This document does not exist in this language (English). You can find it
in another language below.
Slovak (PDF)
Published on: 7/12/2021
How useful was this page?:
